

23rd World Dermatology Congress

June 20-21, 2022 | Paris, France

Isabelle Hansenne-Cervantes, J Dermatol Dis 2022, Volume 09

Clinical efficacy of Bio-Coll@gen in dermatology

Isabelle Hansenne-Cervantes

Modern Meadow, USA

Collagen and its derivative proteins have been widely used as a major compound for skin care products as a natural “skin barrier polymer” and moisturizer. Modern Meadow’s Bio-Coll@gen is a proprietary recombinant protein inspired by human collagen type III that has shown to be safe for application to human skin including sensitive skin. This recombinant protein has reproducibly demonstrated exceptional biostimulation of an array of genes including Collagen III. The unique combination of biostimulation makes this novel recombinant protein a good candidate for broad application in dermatology. Clinical studies have been performed to evaluate the efficacy of the Bio-Coll@gen in anti-ageing with instrumental quantification of the collagen content, barrier function and skin density. In addition, clinical experts have scored the improvement of different parameters and the satisfaction of the consumers has been investigated with a periodic questionnaire.

Biography

Isabelle Hansenne-Cervantes, PHD, Pharm D is a Global R&D Executive with extensive experience in Personal Care, Skin Care, Sun Care and Dermatology products. International Leader of Multiple Functions including Research Innovation, Product Development, Clinical and Safety Studies. She is passionate about bringing new innovative products to market and she is now working for Modern Meadow where she can leverage her biochemistry background and her experience from the cosmetic industry (L’Oreal, Colgate & Coty).

Received: May 11, 2022; **Accepted:** May 13, 2022; **Published:** June 23, 2022
